ClinicalTrials.gg
CompletedNCT07416955Updated Feb 18, 2026

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

A Phase 1 interventional study of TPI-120 Pre-Filled Syringe 6 mg/0.6 mL in Healthy Volunteer, sponsored by Kashiv BioSciences, LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Kashiv BioSciences, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.
  • Registered 10 months after the study started (first participant enrolled Apr 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The Goal of these study is to assess the comparative pharmacokinetics of Test Product (A): TPI-120 Injection 6 mg/0.6 mL solution in a single dose pre-filled autoinjector, manufactured by Kashiv Biosciences LLC, USA with Reference Product (B): TPI-120 Injection 6 mg/0.6 mL solution in a single dose pre-filled syringe manufactured by Kashiv Biosciences LLC, USA in healthy, adult human subjects and also to assess safety and tolerability of investigational product.

Read the detailed description

This study is an open label, randomized, two treatment, two sequence, two period, single dose crossover clinical trial designed to compare the pharmacokinetics, immunogenicity, and safety of Pegfilgrastim TPI 120 (Test) administered via pre filled syringe with auto injector and Fylnetra (Reference) administered via pre filled syringe. The study will be conducted in healthy adult human subjects under fasting conditions.

The study aims to enroll a sufficient number of participants to ensure that 180 healthy subjects complete dosing across both periods. Considering the required procedures and a washout period of at least 34 days between the dosing days of Period I and Period II, the total clinical study duration is approximately 51 days from the first check in. Subjects will be randomized into two treatment sequences and will receive a single subcutaneous dose of either the Test or Reference product in each study period.

The primary objective is to assess the pharmacokinetic (PK) comparability of the two Pegfilgrastim formulations by evaluating PK parameters including Cmax, AUCt, AUCi, Tmax, Kel, AUC%Extrap_obs, and tHalf. PK parameters will be calculated using Phoenix® WinNonlin® (Version 8.1.1 or higher) or SAS® (Version 9.4 or higher). Secondary objectives include assessment of safety and tolerability, as well as immunogenicity through anti drug antibody (ADA) evaluations.

Comprehensive safety assessments will be performed throughout the study. A complete physical examination will be conducted at screening and at the end of the study or early termination, while abbreviated physical examinations will occur during admission of each period, on Day 15 of Period I, and prior to discharge in each period. Clinical laboratory evaluations will include hematology, including absolute neutrophil count (ANC), coagulation (PT/INR), clinical chemistry, and urinalysis, performed at defined time points: screening, check in of Period 1, two days prior to Period 2 check in, Day 15 of Period I, and end of study or early termination.

A 12 lead ECG will be performed at screening, on Day 15 of Period I post dose, and at the end of the study or early termination. Safety screening also includes urine drug screens for drugs of abuse (amphetamine/methamphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates, methadone, and phencyclidine) and alcohol breathalyzer testing at screening and prior to admission of each study period.

Subjects will be closely monitored for adverse events (AEs), serious adverse events (SAEs), changes in laboratory parameters, vital signs, and any clinically significant abnormalities. Immunogenicity evaluations will be performed at protocol specified time points to assess the presence of ADAs and potential neutralizing antibodies.

This study is designed to generate robust comparative PK, safety, and immunogenicity data to support the evaluation of biosimilar comparability between Pegfilgrastim TPI 120 and Fylnetra under fasting conditions in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Pegfilgrastim
03

In context

Lead sponsor

Kashiv BioSciences, LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted before Kashiv BioSciences, LLC became part of Amneal Pharmaceuticals, Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 55 years of age, both inclusive, at the time of consent.
  2. Gender: Male and/or non-pregnant, non-lactating female.
  3. Willing to provide written to participate in the study.
  4. Able to communicate effectively with study personnel.
  5. Subject having weight greater than or equal to 50 kg
  6. : 19.0 to 30.0 kg/m2, both inclusive
  7. Non-smoker and non-tobacco/non-nicotine user (i.e., having no past history of smoking and tobacco/nicotine consuming for at least one year prior to screening).
  8. Alcohol breathalyzer test result must be negative during screening and prior to Period 1 dosing.
  9. Negative urine drug screen including amphetamine/methamphetamine, barbiturates, benzodiazepines, cannabinoid, cocaine, opiates, methadone and phencyclidine during screening and prior to Period 1 dosing.
  10. The subject has a normal (12 leads) as per the investigator judgement, at screening and on admission day (before admission) of period 1.
  11. Subject complies with injection site evaluation at screening and on admission day (before admission) of period 1.
  12. The subject result of is within normal range or ± 5% of medical lab reference range at screening

Exclusion criteria

Exclusion Criteria:

  1. History of antibodies or allergic responses to pegfilgrastim, filgrastim or other GCSF stimulant medications or other related drugs, or any of its formulation ingredients.
  2. Any infection, cough or fever or suffered an acute illness within 1 week prior to first study drug administration.
  3. Subject having hematologic laboratory abnormalities
  4. The subject has been hospitalized within three months before the study or during the study
  5. The subject has been participating in any clinical study (e.g., pharmacokinetics, bioavailability and bioequivalence studies) within the last 30 days prior to the present study
  6. vital sign abnormalities
  7. Positive hepatitis screen (includes subtypes B \& C) and/or a positive test result for antibody.
  8. Study participants who have received a known drug within 30 days or within seven elimination half-lives of the administered drug prior to the initial dose of study drug, whichever is greater.
  9. Study participant who has donated blood and/or had a blood loss of approximately 1 unit or 450 mL within 90 days prior to the initial dosing of the study drug and/or study participant who had blood loss, excluding volume drawn at screening for this study, prior to initial dosing of study drug, whichever is greater
  10. Study participant who has a condition or is taking or has taken a medication that, in the Investigator's judgment, makes the study participant ineligible or places the study participant at undue risk
  11. Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the study participant's participation in this study.
  12. Unavailable for any confinement days or scheduled visits.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    TPI-120 Pre-Filled Syringe 6 mg/0.6 mL with auto injector

    Intervention Group

    Biological: TPI-120 Pre-Filled Syringe 6 mg/0.6 mL

  • Active comparator
    Fylnetra Pre-Filled Syringe 6 mg/0.6 mL

    Comparator Group

    Biological: TPI-120 Pre-Filled Syringe 6 mg/0.6 mL

Interventions

  • BiologicalTPI-120 Pre-Filled Syringe 6 mg/0.6 mL

    TPI-120 Pre-Filled Syringe 6 mg/0.6 mL with auto injector - Manufactured/supplied by: Kashiv Biosciences LLC, USA

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameter

    Cmax,

    Time frame: Baseline to Day 15

  2. Pharmacokinetic parameter

    AUCt

    Time frame: Time Frame: Baseline to Day 15

  3. Pharmacokinetic parameter

    AUC0-inf

    Time frame: Time Frame: Baseline to Day 15

07

Study locations

1 site
  • Cliantha Research
    St. Petersburg, Florida 33714, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Oct 2025, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 18, 2026
StartActual
Apr 5, 2025
Primary completionActual
Oct 10, 2025
CompletionActual
Oct 10, 2025
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07416955
Collaborators
Cliantha Research
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Apr 5, 2025
Primary completion
Oct 10, 2025
Completion
Oct 10, 2025
Last update
Feb 18, 2026

Study contacts

Tamatha F Zemzars, MD
principal investigator · Cliantha Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion